The research project “Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma” coded ERANET TRANSCAN-GRAN-T-MTC (Ε11820) with a 3-year duration (2013-2016) is coordinated by Dr. T. Maina-Nock. It ιs a research cooperation of the Molecular Radiopharmacy team with a European research and clinical centers is sponsored by the EU and the GSRT. It is aiming at the development of the theranostic [¹¹¹In]In/[¹⁷⁷Lu]Lu-CP04 radiopeptide in a pharmaceutical formulation (radiopharmaceutical precursor kit) and the preparation and implementation of clinical evaluation in MTC patients.